Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

BACKGROUND: In 2005, the FDA cautioned that exposure to paroxetine, a selective serotonin reuptake inhibitor (SSRI), during the first trimester of pregnancy may increase the risk of cardiac malformations. Since then, the association between maternal use of SSRIs during pregnancy and congenital malfo...

Full description

Saved in:
Bibliographic Details
Published in:BMC Med
Main Authors: Gao, Shan-Yan, Wu, Qi-Jun, Sun, Ce, Zhang, Tie-Ning, Shen, Zi-Qi, Liu, Cai-Xia, Gong, Ting-Ting, Xu, Xin, Ji, Chao, Huang, Dong-Hui, Chang, Qing, Zhao, Yu-Hong
Format: Artigo
Language:Inglês
Published: BioMed Central 2018
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6231277/
https://ncbi.nlm.nih.gov/pubmed/30415641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-018-1193-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items